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The lack of small-molecule inhibitors for anion-
selective transporters and channels has impeded
our understanding of the complex mechanisms that
underlie ion passage. The ubiquitous CLC ‘‘Chloride
Channel’’ family represents a unique target for
biophysical and biochemical studies because its
distinctive protein fold supports both passive chlo-
ride channels and secondary-active chloride-proton
transporters. Here, we describe the synthesis and
characterization of a specific small-molecule inhib-
itor directed against a CLC antiporter (ClC-ec1).
This compound, 4,4’-octanamidostilbene-2,20-disul-
fonate (OADS), inhibits ClC-ec1 with low micromolar
affinity and has no specific effect on a CLC channel
(ClC-1). Inhibition of ClC-ec1 occurs by binding to
two distinct intracellular sites. The location of these
sites and the lipid dependence of inhibition suggest
potential mechanisms of action. This compound
will empower research to elucidate differences
between antiporter and channel mechanisms and
to develop treatments for CLC-mediated disorders.
INTRODUCTION
Small-molecule modulators of ion channels and transporters
have a rich history as tools for uncovering mechanisms of ion
permeation and as therapeutic agents in the treatment of
disease (Gupta, 2011; Yan, 2010). However, the availability of
small-molecule modulators and the resulting scientific advances
have overwhelmingly favored the broad family of cation-selec-
tive channels and transporters. The study of their anion-selective
counterparts—and the treatment of diseases related to anion
transport (Planells-Cases and Jentsch, 2009; Verkman and1460 Chemistry & Biology 19, 1460–1470, November 21, 2012 ª2012Galietta, 2009)—have been hindered by a general lack of
anion-transport modulators. Here we describe a new, to our
knowledge, small-molecule inhibitor for one family of anion-
transport proteins, the CLC ‘‘Chloride Channel’’ family. The
availability of such compounds will enable further studies to
understand one of the most intriguing aspects of ion transport
in the CLC family—the ability of the same general structure to
support either passive Cl transport or active Cl/H+ antiport.
Our findings provide a foundation for the design of new pharma-
cological agents for studying CLC-mediated physiological
processes, including epithelial ion transport, neuronal and skel-
etal muscle excitability, hippocampal neuroprotection, cardiac
pacemaker activity, endocytosis, and lysosomal acidification
(Graves, et al., 2008; Huang, et al., 2009; Jentsch, 2008; Jewor-
utzki, et al., 2012; Lossin and George, 2008; Nighot, et al., 2009;
Ratte´ and Prescott, 2011), and for treating CLC-related disor-
ders, including osteoporosis, neurodegeneration, and cardio-
vascular disease (Duan, 2011; Jentsch, 2008; Liantonio, et al.,
2012; Zhao, et al., 2009).
In expanding the list of CLCmodulators, we focused on finding
inhibitors of the CLC antiporter from Escherichia coli, ClC-ec1
(Dutzler, 2006; Maduke, et al., 1999). We chose this particular
protein because it is an excellent structural model for other
CLC members (Engh and Maduke, 2005; Este´vez, et al., 2003;
Lin and Chen, 2003) and it can be produced and purified in large
quantities for analysis by multiple biophysical and biochemical
techniques. To date, the only known small-molecule inhibitor
of a CLC antiporter was 4,40-diisothiocyano-2,20-stilbenedisul-
fonic acid (DIDS) (Matulef and Maduke, 2005), which inhibits
many different transporters and channels. DIDS is of limited
practical utility because of its low-affinity, promiscuous binding
(Cabantchik and Greger, 1992) and instability in aqueous solu-
tion (Jakobsen and Horobin, 1989). This instability leads to the
formation of polythiourea compounds, which are more stable
than DIDS and are more potent inhibitors of ClC-ec1 (Matulef,
et al., 2008). These compounds, however, possess two major
disadvantages that limit their usefulness. First, they are large,Elsevier Ltd All rights reserved
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Unique Binding Mode of a Designed CLC Inhibitorconjugated molecules that are impractical to synthesize and
modify for structure-activity investigations. Second, the poly-
thiourea inhibitors cause aggregation of detergent-solubilized
protein, thus precluding crystallographic or spectroscopic char-
acterization of the binding site. Here, we introduce a new, to our
knowledge, ClC-ec1 inhibitor design, 4,4’-octanamidostilbene-
2,20-disulfonate or ‘‘OADS,’’ and provide a comprehensive series
of experiments to elucidate the details of its molecular interac-
tions with the protein.
In the context of the CLC family, OADS offers a unique oppor-
tunity to study differences and similarities between two major
classes of membrane proteins. Although CLCs originally were
thought to be solely voltage-gated Cl channels, many are
Cl/H+ antiporters (Accardi and Miller, 2004; Picollo and Pusch,
2005; Scheel, et al., 2005). Selective CLC inhibitors thus offer the
potential to become tools to probe how these two ostensibly
different ion transport processes can be supported by closely
related protein structures (as deduced by sequence similarity
together with compelling structure-function analyses) (Engh
and Maduke, 2005; Este´vez, et al., 2003; Lin and Chen, 2003;
Lı´sal and Maduke, 2009; Miller, 2006). The classic ‘‘chloride-
channel inhibitors’’ have broad specificity, inhibiting many types
of Cl channels and transporters, and even cation channels
(Alper, 2009; Chen, et al., 2007; Evanko, et al., 2004; Kasai,
et al., 1999; Li, et al., 2008). OADS is highly effective against
the Cl/H+ antiporter ClC-ec1 but has little activity against
a CLC from the channel branch of the family, suggesting that
the differences between permeation and active transport may
be teased apart using molecular probes. To our knowledge,
OADS also is the first inhibitor of the CLC antiporters that is
reversible, has low molecular weight (<1000 Da), and is
amenable to structural modification. We capitalize on these
properties to characterize inhibitor binding, thus providing
a basis for developing future generations of CLC-specific inhib-
itors that eventually may have therapeutic application in treating
osteoporosis and neurodegenerative and cardiovascular
diseases (Duan, 2011; Liantonio, et al., 2012; Zhao, et al., 2009).
RESULTS
Chemical Combination of Generic Cl–-Channel
Inhibitors Yields a Potent CLC Antiporter Inhibitor
In our search for modulators of CLC function, we tested known
CLC channel inhibitors as lead compounds. This panel included
flufenamic acid, the clofibric acid derivative 2-(p-chlorophe-
noxy)-3-(4-chlorophenyl)propionic acid, 9-anthracene carbox-
ylate (9AC), 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB),
niflumic acid, octanoic acid, and 4,4’-diaminostilbene-2,20-disul-
fonate (DADS) (Este´vez, et al., 2003; Gradogna and Pusch, 2010;
Venglarik, et al., 1994; Zhang and Chen, 2009). None of these
compounds inhibited ClC-ec1; however, a modified compound
(OADS) combiningDADSwith two aliphatic side chainsmimicking
the hydrophobic element of octanoic acid (Figure 1A) inhibited
ClC-ec1 at low-micromolar concentrations.
We first assessed OADS’ inhibition of ClC-ec1 using a Cl
efflux assay (Walden, et al., 2007), where ClC-ec1 is reconsti-
tuted into liposomes containing a high internal chloride concen-
tration relative to the extraliposomal buffer, and activity is
measured as the rate at which the protein passes Cl alongChemistry & Biology 19, 1460–147this steep concentration gradient (Figure 1B). OADS inhibited
ClC-ec1 with a concentration for half-maximal inhibition (Ki) of
29 mM (Figure 1C, black circles), whereas neither parent com-
pound detectably inhibited ClC-ec1 (Figure 1C, blue circles
and triangles) at concentrations up to 1 mM (not shown). Thus,
the chemical combination of two conventional Cl channel inhib-
itors (octanoic acid and DADS) results in an increase in potency
compared to either parent compound by well over 100-fold.
We also examined ClC-ec1 inhibition by OADS using bilayer
recordings, which allow for precise control of transmembrane
voltage and solutions on both sides of the membrane (Miller,
1983). In these experiments, ClC-ec1-reconstituted liposomes
were fused to planar lipid bilayers, and the ionic currents carried
by ClC-ec1 were measured under voltage clamp. OADS was
then perfused onto one side of the bilayer, and the degree of inhi-
bition was recorded (Figure 1D). We observe maximal inhibition
of 40% when OADS is added to the cis chamber (Figure 1E).
Because CLC-ec1 inserts into bilayers with random orientation
(Matulef and Maduke, 2005) and OADS is a side-specific inhib-
itor (as shown below), the maximal inhibition possible in these
experiments is 50%. In contrast, in the Cl efflux assays,
OADS is allowed access to both sides of the membrane through
freeze fracture of liposomes during their preparation, thereby al-
lowing nearly complete inhibition (Figure 1C). In bilayers, the
modest increase in potency from Ki 3.6 mM at +100 mV to
2.7 mMat100 mV (Figure 1E) is consistent with the negatively
charged inhibitor sensing part of the transmembrane electric
field on its way to the inhibitory binding site (Woodhull, 1973).
Inhibition by OADS is completely reversible within 4–10 min
(with 4 min being the minimum amount of time required for full
solution exchange of the bilayer chamber) (Figure 1F).
The Ki values measured in bilayers (3 mM, Figure 1E) are an
order of magnitude lower than the values determined using the
Cl efflux assay (30 mM, Figure 1C, black circles). Given the
sensitivity of ClC-ec1 activity tomembrane composition (Robert-
son, et al., 2010) (Figure S1 available online), we hypothesized
that the different Ki values could be due to the presence of an
additional negatively charged lipid (cardiolipin) in the E. coli lipid
extract used for the efflux assays, which was not present in the
bilayer experiments. To test whether the presence of cardiolipin
(CLN) affects OADS potency, we did Cl efflux assays on ClC-
ec1 reconstituted into liposomes composed of a defined lipid
mixture identical to that used in the bilayer experiments (with
phosphatidylethanolamine [PE] and phosphatidylglycerol [PG]
head groups and lacking CLN) (PE/PG liposomes). Consistent
with our hypothesis, the change in lipid composition decreased
Ki from 29 to 7.3 mM, (Figure 1G, triangles), close to that
observed in the planar bilayer experiments. Substituting CLN
for PG restores the Ki to that observed in the original E.coli polar
lipid liposomes (Figure 1G, blue and black circles). These data
indicate that inhibition of ClC-ec1 by OADS is sensitive to the
lipid bilayer composition.
OADS Effect on Protein Activity Is Not Solely Mediated
by Bilayer Modification
With a Ki as low as 3 mM (in PE/PG membranes, Figure 1E),
OADS is among the most potent CLC inhibitors, as well as the
only well-behaved small-molecule inhibitor of any CLC anti-
porter. But the dependence of ClC-ec1 activity and OADS0, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1461
Figure 1. OADS Is a CLCAntiporter Inhibitor
(A) Synthesis of OADS from the generic chloride
channel inhibitors octanoic acid and DADS.
(B) Raw data from Cl efflux assays. ClC-ec1 is
reconstituted into liposomes, and efflux is initiated
by the addition of valinomycin; Triton X-100 is
added at the end of each experiment to release all
of the chloride from the liposomes (see Experi-
mental Procedures for more details).
(C) Concentration dependence of ClC-ec1 inhibi-
tion in Cl efflux assays. Each data point repre-
sents the mean inhibition ± standard error of
the mean (SEM) for three to seven experiments
at each concentration. For OADS, the solid line is
a fit of the data to the equation: I= ðImax3
½OADSnÞ=ðKni + ½OADSnÞ; where I is the per-
centage inhibition, Imax is the maximal inhibition, Ki
(29 mM) is the apparent affinity, and n (1.9) is the Hill
coefficient.
(D) Currents carried by ClC-ec1 in planar lipid
bilayers in response to the voltage protocol shown
below before (left) and after (right) addition of
9.9 mM OADS to one side (the cis chamber) of the
bilayer.
(E) Concentration dependence of the inhibition by
OADS in bilayers. Each data point represents the
mean inhibition ± SEM from three to seven bilayers
with OADS added to the cis chamber. At +100 mV,
Imax = 34%, Ki = 3.4 mM, and n = 3.9. At 100 mV,
Imax = 40%, Ki = 2.9 mM, and n = 6.1.
(F) Reversibility of OADS inhibition in bilayers.
Current-voltage curves before (black) and after
adding 3.3 mM OADS to the trans chamber (blue
squares), and after perfusion with OADS-free
solution (red triangles). Similar results were ob-
tained with two other bilayers, and in all cases
reversal was complete within 4–10 min (with 4 min
being the minimum amount of time required for full
perfusion).
(G) Effect of liposome composition on ClC-ec1
sensitivity to OADS in Cl efflux assays. Data for
E. coli polar lipids are identical to those in panel
(C). For PE/PG liposomes, Ki = 7.3 mM and n = 1.9;
for PE/CLN, Ki = 32 mM and n = 1.5.
See also Figures S1 and S4.
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the question as to whether the inhibition results from a specific
interaction with the protein, from a more general modification
of the lipid bilayer, or from some combination of these mecha-
nisms (Figure 2A).
To address these questions, we employed an assay that
exploits gramicidin channels to distinguish between inhibition
that occurs solely through modification of bilayer properties
and inhibition that involves a direct effect on the protein (Fig-
ure 2B). Briefly, the sensitivity of gramicidin channel activity to
lipid bilayer properties (Lundbaek, et al., 2010) is used to report
on bilayer modification by an exogenously added compound (In-
go´lfsson and Andersen, 2010). On its own, a positive result in the
gramicidin assay may not be remarkable because many druglike
compounds are amphiphiles. Such compounds will therefore
also have bilayer modifying activity (at some concentration) in
addition to their target-specific activity. The power of the assay
lies in its application to a panel of (related) compounds. If1462 Chemistry & Biology 19, 1460–1470, November 21, 2012 ª2012a compound inhibits activity of a membrane protein target solely
through a bilayer-modification mechanism, the target-specific
and the bilayer effects should occur at similar concentrations;
moreover, the bilayer-modifying potency of a panel of related
compounds will be positively correlated with their relative inhib-
itory potency. Conversely, if the compound has specific interac-
tions with the target, the relative inhibitory potency for the set of
compounds will deviate from such a correlation (Ingo´lfsson and
Andersen, 2010). To implement this analysis, we synthesized
and tested a panel of OADS derivatives (Figures 2C–2E). There
is an unmistakable break in the correlation between the two
assays: the cis isomer of OADS is several-fold less potent against
ClC-ec1 than its trans counterpart (Figure 2D), yet it is the more
potent bilayer-modifying compound (Figure 2E). Thus, inhibition
is not solely due to a modification of bilayer properties (mecha-
nisms 4 and 5 in Figure 2A), but rather the predominant mecha-
nismof OADS inhibition of ClC-ec1 occurs through specific inter-
actions with the protein (mechanisms 1, 2, or 3 as in Figure 2A).Elsevier Ltd All rights reserved
Figure 2. Inhibition of ClC-ec1 by OADS
Results Predominantly from Drug-Protein
Interactions
(A) Mechanisms by which drugs can inhibit trans-
porter function: (1) Occluding the transport path to
block ion movement; (2) binding to sites formed by
the protein, to alter function by altering the free
energy difference between different conforma-
tions; (3) binding to selective sites at the protein/
bilayer interface, which may also alter the bilayer
deformation energy contribution to the free energy
difference between different conformations; (4)
nonspecific accumulation at the protein/bilayer
interface to alter the local lipid packing; and (5)
partitioning at the bilayer/solution interface to alter
lipid bilayer material properties, which both will
alter the bilayer contribution to the membrane
protein’s conformational equilibrium (Modified
after Andersen, 2008).
(B) Changes in bilayer properties can be deter-
mined by measuring changes in the gramicidin
(gA) monomer4dimer equilibrium (e.g., Lund-
baek, et al., 2010) because the hydrophobic length
of the bilayer-spanning, ion conducting, dimeric
gA channel is less than the hydrophobic length of
the host bilayer. gA channel formation therefore
leads to a local membrane thinning, with an
associated energetic cost that varies with changes
in the bilayer properties, thus making gA channels
suitable probes for changes in bilayer properties.
(C) Panel of OADS derivatives tested for ClC-ec1
potency and bilayer modification: OADS, cis-
OADS, H2OADS, DADS, and octanoic acid.
(D) Dose-response curves for inhibition of ClC-ec1
activity by OADS derivatives, as determined by
Cl-efflux assays on liposomes formed from
E. coli polar lipids (as in Figures 1B and 1C). Each
data point represents the mean inhibition ± SEM
for three to five experiments at each concentration, with the exception of H2OADS points, which represent the average of two experiments ± range.
(E) Dose-response curves for the OADS derivatives’ effects on bilayer properties, as reported by increases in gA activity. gA activity is determined from the time
course of Tl+-induced quenching of a fluorophore encapsulated in gA-doped large unilamellar liposomes (see Experimental Procedures for more details). The
quench rate in the presence of a compound normalized to the rate in the absence of added compound reflects the degree of bilayer modification (Ingo´lfsson and
Andersen, 2010).
Chemistry & Biology
Unique Binding Mode of a Designed CLC InhibitorOADS Selectively Inhibits the CLC Antiporter ClC-ec1
over the CLC Channel ClC-1
Having established that OADS inhibits ClC-ec1 through specific
interactions with the protein, we next sought to address whether
OADS (like other stilbene derivatives) also acts as a broad-
spectrum inhibitor of chloride channels or whether it displays
selectivity toward the chloride-proton antiporter ClC-ec1.
OADS was tested for activity against the CLC chloride channel
ClC-1 using inside-out patches excised from Xenopus oocytes
expressing human ClC-1. As shown in Figures 3A and 3C,
30 mM OADS (which inhibits ClC-ec1 by 84% in PE/PG lipo-
somes) inhibits ClC-1 by only 20%. This low potency of OADS
toward ClC-1 could be solely due to the lipid composition of
the oocyte membrane, given the previously noted influence of
lipids on inhibition by OADS (Figure 1). Accordingly, it is informa-
tive to compare the cis and trans isomers of OADS within each
environment. In contrast to inhibition of ClC-ec1, similar degrees
of ClC-1 inhibition are observed with both cis and trans OADS
isomers (Figures 3B and 3C). This result suggests that the cis
isomer of OADS acts through a more generic mechanism (suchChemistry & Biology 19, 1460–147as bilayer modification, as discussed above), whereas the trans
isomer (‘‘OADS’’, Figure 2B) acts through more specific molec-
ular contact with ClC-ec1.
OADS Binds to and Inhibits ClC-ec1 with a 2:1
Stoichiometry
In the chloride efflux assays, the inhibition curves are best fit with
a Hill coefficient of 1.9, which suggests that ClC-ec1 inhibition
requires at least two OADS to bind per protein subunit (Fig-
ure 1C). ClC-ec1 is a homodimer, with each monomer acting
as an independent transporting unit (Robertson, et al., 2010). In
bilayer recordings, the Hill coefficient for OADS inhibition ranges
from 3.9 at +100 mV to 6.1 at 100 mV (Figure 1E). Given that
OADS has some bilayer-modifying activity (Figure 2D), the larger
Hill coefficient in the latter experiments could be due to OADS
interacting with the bilayer and not directly with the protein. To
focus on the protein-specific aspect of OADS binding to and
inhibition of ClC-ec1, we investigated the covalent binding of
a photoreactive OADS derivative with detergent-solubilized
protein. Covalent modification of ClC-ec1 by this reagent allows0, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1463
Figure 3. OADS Is a Selective CLC Inhibitor
(A) Representative current families from inside-out patches excised from
Xenopus oocytes expressing human ClC-1. Currents before (left) and after
(right) steady-state inhibition in 30 mM OADS were elicited by the voltage
protocol shown below the traces.
(B) ClC-1 currents as in (A) but with 30 mM cis-OADS.
(C) Summary data comparing inhibition of ClC-1 by OADS and cis-OADS (left)
to inhibition of ClC-ec1 by OADS and cis-OADS (right). ClC-ec1 was recon-
stituted in PE/PG liposomes and measured in Cl efflux assays. For each
experiment, data represent the mean ± SEM for three experiments.
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molecules bound per protein subunit. By quantifying the Cl
flux activity of the modified protein, we then could determine
how many bound OADS molecules are necessary and sufficient
for inhibition.
To synthesize an OADS analog suitable for photoaffinity
labeling, we chose a diazirine photophore, because this func-
tional group only slightly perturbs the OADS structure, its photo-
activation generates an electrophilic carbene that can react with
any nearby C–H, N–H, or O–H bond, and it is activated at 365 nm,
a wavelength that will not induce photolytic protein damage
(Dorma´n and Prestwich, 2000). The synthesis of a diazirine-
OADS photoaffinity-labeling reagent (‘‘PAL-OADS’’) is shown in
Figure S2A. The Ki of PAL-OADS for ClC-ec1 is 80 mM, as deter-
mined by the Cl efflux assay in E. coli polar lipids (Figure S2B),
a 2- to-3-fold increase compared to OADS (Figure 1C).
In liposomes, irreversible inhibition by PAL-OADS was ob-
served only when the sample was irradiated with 365-nm light,1464 Chemistry & Biology 19, 1460–1470, November 21, 2012 ª2012thus confirming that PAL-OADS acts as a light-dependent cova-
lent inhibitor (Figure S2C). To quantify the relationship between
photo-incorporation and inhibition, solubilized ClC-ec1 was
incubated with PAL-OADS and irradiated with 365 nm light.
These samples were then split into aliquots for either analysis
by mass spectrometry or reconstitution into liposomes for
activity analysis (Figures 4A–4C). The sample labeled with the
lower concentration of PAL-OADS showed no inhibition relative
to unmodified ClC-ec1, though 40% of the protein was modified
by a single OADS molecule (Figure 4C, middle); this result indi-
cates that binding of one equivalent of OADS per ClC-ec1 is
not sufficient to inhibit function. The sample labeled with the
higher concentration of PAL-OADS (400 mM) was inhibited
62% (Figure 4C, right), which best correlates to the amount of
protein that is at least doubly labeled (44%), but not to the
amount that is triply labeled (10%). These results are consistent
with the Hill coefficient of2 determined in the Cl efflux assays
(Figure 1B) and demonstrate that the binding of two OADSmole-
cules per subunit is necessary and sufficient for inhibition.
Inhibition by OADS Is Mediated by Binding to Two
Distinct Intracellular Sites
Having established that direct binding of OADS to ClC-ec1 is
responsible for inhibition, we sought to obtain structural details
of the inhibitor-binding sites. ClC-ec1 crystals grown in the pres-
ence of (or soaked with) OADS failed to reveal density corre-
sponding to the small molecule. An alternative strategy using
PAL-OADS in combination with ‘‘top-down’’ mass spectrometry
(MS) was, therefore, explored (Robinette, et al., 2006). Top-down
MS uses high-resolution Fourier-transform mass spectrometry
to measure the intact mass of the protein in combination
with fragmentation either by collisionally activated or electron-
capture dissociation (CAD/ECD), producing product ions for
tandem mass spectrometry whose masses are sequence and
modification specific (Kelleher, 2004). Analysis of the single-
labeled protein revealed a binding site localized within residues
109 and 185 of ClC-ec1; analysis of the double-labeled protein
revealed a second locale within the first 40 residues of the
N terminus (Figure 5A; Figure S3; Tables S1 and S2).
The MS data show that both OADS-binding sites are localized
to the intracellular side of the membrane. This result cannot be
compared directly with our functional assays because reconsti-
tuted ClC-ec1 adopts mixed orientations in liposomes and
bilayers. We can achieve ‘‘functional orientation,’’ however, by
taking advantage of the fact that DIDS inhibits ClC-ec1 specifi-
cally from the intracellular side, as demonstrated in bilayer
recordings (Matulef andMaduke, 2005). Figure 5B shows a sche-
matic representation of transporters oriented within a bilayer in
opposite directions relative to the two bilayer chambers (called
cis and trans). If OADS inhibits exclusively from the intracellular
side, the addition of OADS to the cis chamber after addition of
DIDS to the same chamber should have no further effect (Fig-
ure 5B, case 1). In contrast, if OADS inhibits from the extracellular
side, the addition of OADS to the cis chamber after addition of
DIDS to the same chamber should cause further inhibition
(Figure 5B, case 2). We observe that application of OADS
following addition of DIDS to the same chamber has no effect,
consistent with Case 1 (Figure 5C). Likewise, the application of
DIDS following addition of OADS to the same chamber has noElsevier Ltd All rights reserved
Figure 4. Binding Two Molecules of OADS
per ClC-ec1 Protein Subunit Is Necessary
and Sufficient to Inhibit ClC-ec1 Function
(A) Experimental schematic: cross-linked protein
was subjected to mass spectrometry analysis, as
in (B), and functional studies (reconstitution and
Cl- efflux assays, as in Figures 1B and 1C).
(B) Covalent modification of ClC-ec1 with 400 mM
PAL-OADS detected by mass spectrometry.
(C) Comparison of percentage of inhibition of ClC-
ec1 activity measured using Cl efflux (blue bars)
to percentage of ClC-ec1 that is singly, doubly, and
triply modified (light orange, medium orange, and
brown bars, respectively). ClC-ec1 in the presence
of 0, 100, or 400 mMPAL-OADSwas irradiatedwith
365 nm light UV and then split into two samples as
illustrated in panel (A). ‘‘Singly modified’’ corre-
sponds to percentage of ClC-ec1 covalently linked
to at least one equivalent of PAL-OADS (sum of
singly, doubly, and triply modified protein), de-
tected by mass spectrometry as in panel (B).
‘‘Doubly modified’’ corresponds to percentage of
ClC-ec1 covalently linked to at least two equivalents of PAL-OADS (sum of doubly and triply modified protein). ‘‘Triply modified’’ corresponds to percentage
of ClC-ec1 covalently linked to three equivalents of OADS. The combined results demonstrate that (1) binding of one OADSmolecule to ClC-ec1 does not inhibit
ClC-ec1 (middle, results with 100 uMPAL-OADS), (2) binding of twoOADSmolecules correlates well with inhibition (right, results with 400 mMPAL-OADS), and (3)
binding of three OADS molecules is not required for inhibition (right, results with 400 mM OADS). Results represent the mean of three experiments (±SEM).
See also Figure S2.
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Unique Binding Mode of a Designed CLC Inhibitoreffect (Figure S4A). In further support of this model, the applica-
tion of OADS to the opposite chamber from DIDS results in
significant additional inhibition (Figures S4B and S4D), as does
application of DIDS to the opposite chamber from OADS
(Figures S4C and S4D). Hence, OADS inhibits ClC-ec1 from
the intracellular side, in agreement with the mass spectrometry
results.
To confirm and further refine the location of the OADS-binding
sites, we tested the functional effect of mutations in each of the
regions identified through mass spectrometry. We targeted
cationic amino acid residues, reasoning that neutralization of
such residues near the binding pockets would decrease affinity
of the dianionic OADS molecule. Figure S5 shows a summary
of the mutations that had no (or very little) effect on Ki for
OADS. Of the residues tested, two sites were found in which
neutralization disrupted OADS inhibition. Within the first region
identified by MS (residues 109–185; Figure 5A), the K169A
mutant exhibited a 2-fold decrease in sensitivity to OADS
(Ki = 68 mM), whereas mutating the three nearby arginine resi-
dues (R160, R167, and R174, located within 5 A˚ of K169) had
no influence (Figure 6A; Figure S5A). This result indicates that
a mutation at K169 changes OADS affinity through disruption
of a specific interaction rather than through a more general elec-
trostatic effect. Within the second region identified by MS (resi-
dues 15–40; Figure 5A), we found that R28A in combination
with K216A (which is within 9 A˚ in 3-dimensional space) elimi-
nated all detectable inhibition in PE/PG lipids (Figure 6B) and
reduced the inhibition in E. coli lipids several fold (Figure 6A).
The residual inhibition in E. coli lipids is similar to the inhibition
observed with cis-OADS (Figure 6C). Ki values could not be
determined for the R28A/K216Amutant because of the solubility
limit of OADS (100 mM). This decrease in OADS affinity for mutant
ClC-ec1 is specific to R28/K216, as mutation of R23 and K30 or
R17, R18, and R19 had no effect on OADS inhibition (Figure S5).Chemistry & Biology 19, 1460–147Simulations of OADS:ClC-ec1 Binding in a Lipid Bilayer
We also studied the binding of OADS to ClC-ec1 by atomistic
molecular dynamics simulations in POPE/POPG (3:1) mem-
branes, which were done without prior knowledge of any exper-
imental data concerning the OADS binding sites. Figure 7A
shows the simulation system. In five simulations (each 30–
85 ns, with a total simulation time of 265 ns), six to eight OADS
molecules were inserted in the aqueous phase near the mem-
brane. Most OADS molecules rapidly moved to the membrane/
solution interface (not all molecules had entered the interfacial
region at the time the snapshot in Figure 7A was taken), with
the OADS sulfate groups interacting with the phospholipid
head groups. Contacts between OADS and K169 were observed
in two simulations; contacts between OADS and the region near
R28 and K216 were observed in three simulations. Both interac-
tions were observed in one simulation, where two OADS mole-
cules associated with the intracellular side of ClC-ec1: one of
them formed a tight ionic interaction between K169 and the
anionic sulfate on OADS; the second interacted with a larger
region of the adjoining ClC-ec1 subunit near K216 and R28,
involving a contact to the backbone of R28 (Figures 7B and
7C). The limited timescale of the simulations does not allow
conclusions about the thermodynamic stability of these binding
modes, but the results lend further support to our experimental
data implicating K169 and R28/K216 as specific, functionally
relevant sites of OADS binding to ClC-ec1.
DISCUSSION
Despite recent progress in the generation of CLC-specific inhib-
itors of certain homologs, including a scorpion venom toxin
specific for ClC-2 (Thompson, et al., 2009) and small-molecule
inhibitors of the ClC-K channels (Gradogna and Pusch, 2010;
Liantonio, et al., 2008), the CLCs lack the extensive array of0, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1465
Figure 5. Binding and Inhibition by OADS
Occurs at Two Distinct Intracellular Sites
(A) ‘‘Top-down’’ mass spectrometry was used to
identify the OADS-binding regions in ClC-ec1. The
ClC-ec1 structure illustrates the identified region of
labeling of the singly modified protein in orange
(residues 109–185) and an additional site identified
in the doubly modified protein in cyan (residues
15–40). The singly modified protein was modified
only at the 109–185 site and not at the 15–40 site;
the doubly modified protein was modified at both
locations. The two subunits are depicted in blue
and gray, and Cl ions are space-filled in green.
(B) Schematic cartoons depicting side-specific
inhibition of ClC-ec1 by OADS. ClC-ec1 protein is
randomly oriented in bilayers. Case I shows that if
OADS, like DIDS, acts from the intracellular side,
adding OADS to the cis chamber after addition of
DIDS will have no effect. Case 2 shows that if
OADS acts from the extracellular side, adding
OADS to the cis chamber after addition of DIDS
should cause further inhibition.
(C) Current-voltage curves obtained in bilayer
recording experiments before (black circles) and
after adding 1 mM DIDS to the cis chamber (blue
triangles), and after subsequent addition of 15 mM
OADS to the cis chamber (orange circles). That no
additional inhibitionwas observed upon addition of
OADS is consistent with Case 1, with OADS inhi-
bition occurring at the intracellular side of ClC-ec1.
See also Figures S3 and S4 and Tables S1 and S2.
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proteins. We have developed and characterized a novel CLC
inhibitor, ‘‘OADS’’ which, to our knowledge, is the first small-
molecule inhibitor of CLC antiporters that is of sufficient affinity
and stability to be used in both functional and biochemical
studies. OADS was created through the combination of two
generic chloride-channel inhibitors, each of which shows no
efficacy against ClC-ec1. The maximal observed affinity of
OADS for ClC-ec1 (Ki 3 mM) is well within the range of typical
lead compounds, and we anticipate that further iterative modifi-
cation (performed in tandemwith functional studies), will result in
improved next-generation inhibitors that will facilitate atomistic
studies of these important membrane proteins.
The information we have gathered on OADS binding and inhi-
bition of ClC-ec1 provide insight into possible mechanisms of
inhibition. Functional and mass spectrometric analysis of the
singly modified protein (Figures 4C and 4D) shows that binding
at a single site between residues 109 and 185 occurs first
(because no modification at the second site is observed in the
singly modified protein.) This site involves K169, as evident
from our mutational (Figures 6A, 6C, and 6D) and modeling
(Figures 7B and 7C) studies. However, binding to this site alone
is not sufficient to inhibit function; inhibition is observed only
when OADS is bound to two discrete locations (Figure 4D).
Because binding to the second (R28/K216) site is not observed
in the absence of binding to the K169 site (Figure 5A), we
conclude that binding of OADS at the K169 site is required for
binding to the second site.
Mutating R28 and K216 to alanine eliminates all detectable
inhibition of ClC-ec1 reconstituted in PE/PG and decreases
inhibition in E. coli lipids several fold (Figures 6A and 6B). The1466 Chemistry & Biology 19, 1460–1470, November 21, 2012 ª2012residual inhibition in E. coli lipids may be due to nonspecific
bilayer effects, rather than specific OADS-protein interactions.
The magnitude of such an effect is likely to depend on the bilayer
composition, which could account for the differences between
the inhibition observed in PE/PG versus E. coli lipids. Nonspe-
cific binding, however, cannot be the primary mechanism of
action of OADS on the wild-type protein (as discussed above,
Figure 2), but may account for the residual inhibition observed
in the R28A/K216A mutant. In support of this hypothesis, cis-
OADS (which is more bilayer-modifying but a less effective
inhibitor of wild-type ClC-ec1; Figures 2D, 2E, and 3C) inhibits
the R28A/K216A mutant with similar potency to the trans-
OADS isomer (Figure 6C). Likewise, ClC-1 (which lacks positively
charged residues at the corresponding positions) is inhibited
only 20% by OADS, and is equally inhibited by both the cis
and trans-OADS isomers (Figure 3). Together, these data further
support our model for specific OADS-R28/K216 interactions in
the inhibition of ClC-ec1 and illustrate the importance of testing
for bilayer effects.
Does OADS inhibit eukaryotic CLC antiporters? Addressing
this question is challenging given the low currents exhibited by
eukaryotic CLCs in inside-out patches and the fact that eukary-
otic CLCs have not been functionally reconstituted for use in
either bilayer recordings or efflux assays. Sequence alignments
around the regions that contribute to OADS potency in ClC-ec1
are too wobbly to reliably predict which homologs contain posi-
tively charged residues in positions equivalent to R28, K169, and
K216 (and thus to predict which homologs are sensitive to
OADS). Nevertheless, it is intriguing that, in some alignments,
position 169 (at the site of initial binding) contains a positively
charged residue in most CLC antiporters and a negativelyElsevier Ltd All rights reserved
Figure 6. K169 and R28/K216 Constitute Functionally Relevant
OADS Binding Sites
(A) Cl efflux assays reveal decreased sensitivity of K169 and R28/K216
mutants to OADS. Simultaneous mutation of three other cationic residues,
R164, R160, and R172, all within 5 A˚ of K169 (inset), has no effect on inhibition.
Assays were performed on liposomes formed from E. coli polar lipids. Error
bars indicate SEM for three to seven experiments at each concentration.
(B) Inhibition of R28A/K216A by OADS is not detectable in Cl efflux assays
with PE/PG liposomes. Data for WT are identical to that shown in Figure 1G.
For R28A/K216A, error bars indicate SEM for five experiments at each
concentration.
(C) In contrast to WT ClC-ec1, cis-OADS inhibits R28A/K216A just as potently
as trans-OADS (‘‘OADS’’). Data are from Cl efflux assays on liposomes
formed from E. coli polar lipids. Error bars indicate SEM for three to seven
experiments at each concentration.
See also Figure S6.
Figure 7. OADS Binding to ClC-ec1 at K169 and R28/K216 as
Observed by Atomistic Molecular Dynamics Simulations
(A) Simulation system showing ClC-ec1 (blue/gray) in a lipid bilayer (green) with
OADS (orange). Lower compartment corresponds to the intracellular side of
the protein (see Experimental Procedures for more details of simulation
system).
(B) Stereo view of ClC-ec1 showing that OADS associates with K169 through
an ionic interaction and with R28/K216 through direct contact with the back-
bone of R28. For reference, chloride ions bound to the chloride permeation
pathway of ClC-ec1 are shown space-filled in green.
(C) Rotated view, showing perspective from the cytoplasm.
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Unique Binding Mode of a Designed CLC Inhibitorcharged residue in all of the known channels (Figure S5C). This
observation suggests that OADS might be generally specific
for CLC antiporters over channels.
The effect of cardiolipin (CLN) on both OADS potency (Fig-
ure 1G) and ClC-ec1 activity (Figure S1) suggests a functionally
important CLN-protein interaction in ClC-ec1, perhaps similar
to those observed in other proton-pumping proteins. In the cyto-Chemistry & Biology 19, 1460–147chrome bc1 complex, for example, CLN is thought to serve as
a local buffer capable of directly feeding protons into the ion
permeation path (Haines and Dencher, 2002; Lange, et al.,
2001). Consistent with CLN playing such a role in H+ transfer
by ClC-ec1, Cl efflux at pH 4.5 (slightly above the pH 4.0
used in the assays reported here) is robust in PE/CLN liposomes
but severely reduced in PE/PG (in the absence of CLN) (Fig-
ure S1). OADS (Figure 1A) shares some basic structural features
with CLN (including the presence of two central negative charges
flanked by hydrocarbon chains). Thus, owing to the higher
potency of OADS the absence of CLN (Figures 1E and 1G), it is
tempting to speculate that OADS andCLN compete for a binding0, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1467
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direct competition is unlikely, however, given that the R28A/
K216A mutant has similar activity to wild-type ClC-ec1.
How does OADS binding impact ClC-ec1 function? The loca-
tion of the OADS binding sites—away from the Cl-permeation
pathway (Figures 5A and 7B) —shows that OADS is not a classic
‘‘pore blocker.’’ This conclusion is supported by mutagenesis of
the intracellular vestibule leading to the Cl-permeation path-
way, because simultaneous neutralization of three charged
residues in this region has no effect on inhibition by OADS (Fig-
ure S5A). We can further conclude that OADS does not indirectly
cause occlusion of the chloride permeation pathway because
ITC experiments reveal no significant effect on Cl binding to
ClC-ec1 (Figure S6), Together, these results strongly suggest
that OADS leaves the Cl-permeation pathway intact and acts
either by disrupting the H+- permeation pathway or by hindering
the transition between protein conformations involved in the
Cl/H+ transport cycle (hence slowing transport). The CLN influ-
ence on OADS affinity could thus arise from several possible
mechanisms, including a specific interaction of CLN with the
H+-permeation pathway, a general membrane effect (Lundbaek,
et al., 2010), and/or a propensity for ClC-ec1 to adopt a confor-
mation more favorable to OADS binding without CLN present. If
OADS does indeed act by ‘‘trapping’’ ClC-ec1 in a particular
conformation, then OADSwill be a powerful tool for investigating
CLC conformational states that have been undetected by crys-
tallography but glimpsed by NMR (Elvington, et al., 2009). In
any case, our findings set the stage for inhibitor-driven investiga-
tions to elucidate function in this widespread and distinctive
family of channels and transporters.
SIGNIFICANCE
CLC ‘‘chloride channel’’ proteins are essential for a wide
variety of physiological processes and are distinctive in
that only half of the CLC family members are true chloride
channels, whereas the other half are chloride-proton anti-
porters. Investigations of this unique family of proteins
thus hold promise for generating insight into fundamental
mechanistic distinctions between channels and trans-
porters. The study of CLCs has been hindered, however,
by the lack of an established pharmacology. Here, we begin
to fill this void by identifying and characterizing a compound
that inhibits a CLC antiporter (ClC-ec1) and has little effect
on a CLC channel (ClC-1). This molecule, OADS, was gener-
ated through combination of two generic anion-channel
inhibitors that alone show no efficacy against ClC-ec1.
OADS is a small-molecule inhibitor of the CLC antiporters
that is both stable in solution and amenable to structural
modification. These traits have allowed us to go beyond
pure functional analysis to characterize details of inhibitor-
protein binding. We first used a gramicidin-based assay to
demonstrate that inhibition is due to protein binding rather
than bilayer modification. This technology has broad appli-
cability and vast potential for streamlining drug discovery
efforts. We next used top-downmass spectrometry analysis
and a photoaffinity-labeledOADSderivative to identify inhib-
itor binding sites, thus establishing the feasibility of these
methods with large (50 kDa) integral membrane proteins.1468 Chemistry & Biology 19, 1460–1470, November 21, 2012 ª2012Finally, we used molecular dynamics simulations, mutagen-
esis, and activity assays to substantiate the relevance and
specificity of the identified OADS-binding sites. The identifi-
cation of these sites will aid in further development and
refinement of next-generation CLC inhibitors.
EXPERIMENTAL PROCEDURES
Chemical Syntheses
OADS and its analogs were synthesized as described in the Supplemental
Experimental Procedures.
Expression, Purification, and Reconstitution of ClC-ec1
ClC-ec1 containing a C-terminal polyhistidine tag was overexpressed in
E. coli, purified, and reconstituted as described elsewhere (Accardi, et al.,
2004; Walden, et al., 2007). Reconstituted liposomes were formed from either
E. coli polar lipid extract or synthetic lipids (65% POPE/35% POPG or 65%
POPE and 35% bovine cardiolipin), where POPE is 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine and POPG is 1-palmitoyl-2-oleoyl-sn-glyc-
ero-3-phospho-(1’-rac-glycerol). All lipids were purchased from Avanti Polar
Lipids.
Chloride Efflux Assays
Cl efflux assays were performed as previously described (Matulef, et al.,
2008). The selected inhibitor was diluted from a 2–10 mM stock solution in
H2O to ClC-ec1-containing liposomes (in 300 mM KCl and 25 mM Na
+-citrate
[pH 4.0]). An equal volume of H2Owas added to liposomes containing no inhib-
itor. OADS solubility is limited in salt solution (unlike in pure H2O), and thus
a final OADS concentration of no more than 100 mM was used in these exper-
iments. (In contrast, PAL-OADS remains soluble up to millimolar concentra-
tions in salt solution, and thus higher concentrations could be used in the
mass spectrometry experiments described below.) Intra- and extravesicular
solutions were equalized by freezing and thawing samples four times prior to
extrusion through a 400 nm filter. Extravesicular solution was exchanged for
low-chloride flux buffer (150 mM K2SO4, 50 mM KCl, and 25 mM Na
+-citrate
[pH 4.0]) immediately prior to performing the experiment. Cl efflux was initi-
ated by the addition of the potassium-selective ionophore valinomycin, which
allows bulk electroneutral efflux of KCl, and was monitored using an extrave-
sicular AgCl electrode. The turnover rate is defined as the initial rate of Cl
efflux minus the initial efflux through control liposomes containing no ClC-ec1,
divided by the number of ClC-ec1 molecules in the assay (Cl s1 ClC-ec11)
(quantified as described by Walden et al., 2007, using an extinction coefficient
of 0.85 cm2/mg). Triton X-100 (0.1%) was added at the end of each assay as
a control to reveal the total chloride.
Electrophysiological Recordings
Bilayer and patch-clamp recording were performed as described previously
(Lı´sal and Maduke, 2009; Matulef and Maduke, 2005). See Supplemental
Experimental Procedures for details.
Measurement of Bilayer Modification by OADS and Its Derivatives
Large unilamellar vesicles (LUVs) were made of 1,2-dierucoyl-sn-glycero-3-
phosphocholine (DC22:1 PC), loadedwith the water-soluble fluorophore 8-ami-
nonaphthalene-1,3,6-trisulfonic acid, disodium salt (ANTS) using a four-part
process of sonication, freeze-thaw cycles, extrusion, and elution. The LUVs
were doped with gramicidin (gA) from B. brevis and incubated for 20–24 hr
at 12.5C. Alternatively, gA containing vesicles were prepared by adding gA
directly to the lipid. Both methods of vesicle preparation were subjected to
the same four-step process and produced consistent control rates. The fluo-
rescence produced by ANTS is quenched by thallium (Tl+). Tl+ and ANTS cross
the bilayer slowly, whereas the conducting gA channels are very Tl+ perme-
able, such that the Tl+ influx rate (the rate of fluorescence quenching) becomes
a measure of the number of conducting gA channels in the LUV membranes.
Tomeasure the fluorescence quench rate, the ANTS-loaded LUVs were mixed
with the Tl+ quencher using a stopped-flow spectrofluorometer (Applied
Photophysics, SX.20), and the fluorescence quench rate was determined
from a stretched-exponential fit to the fluorescence time course, as describedElsevier Ltd All rights reserved
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fluorescent, and background fluorescence was corrected by measuring the
fluorescence time-course in the absence and presence of quencher, thus
enabling correction for the background fluorescence and photobleaching of
the OADS derivatives.
Binding Stoichiometry Determination by Mass Spectrum Analysis
Samples were analyzed by LC-MS on an Agilent 1100 binary pump HPLC and
Thermo Fisher LTQ XL ion trap mass spectrometer. A 75 3 2.1 mm Zorbax
300SB-C3 Poroshell column was employed with initial conditions of 98% A
(0.1% formic acid in water) and 2%B (0.1% formic acid in acetonitrile) ramped
to 95% B in 10 min at a flow of 250 ml/min. Ionization was in positive ESI with
mass range 400–2000 m/z. The injection volume was 10 ml of a 1003 diluted in
H2O sample solution. Promass deconvolution software was used to plot the
data as mass versus intensity.
Top-Down Mass-Spectrometry of Covalently Modified ClC-ec1
ClC-ec1 covalently modified with 500 mM PAL-OADS was precipitated with
chloroform/methanol and dissolved in 100 ml of 90% formic acid (ACS grade,
Fisher). The sample was immediately injected into a size-exclusion chroma-
tography system previously equilibrated with CHCl3/MeOH/1% aqueous for-
mic acid (4:4:1, v/v), as previously described for lactose permease (a protein
that weighs close to 50 kDa and has twelve transmembrane helices) (White-
legge, et al., 1999). Column eluent was directed to a standard electrospray
source (IonMax, Thermo Scientific) attached to a 7 Tesla hybrid linear ion
trap Fourier-transform ion cyclotron resonance mass spectrometer (LTQ-FT
Ultra, Thermo Scientific). The column (SW2000 XL, Tosoh Biosciences) was
eluted with a flow rate of 250 ml/min, which was reduced to 5 ml/min immedi-
ately prior to elution of the protein peak 7 min into the run. This ‘‘peak parking’’
allows extended data collection on OADS/ClC-ec1 (10–90 min). The FT-MS
was operated at 400,000 resolution (at 400 m/z) in order to achieve unit reso-
lution of 13C isotopomers. The mass spectrum was then transformed to the
zero charge state using Xtract software (Xcaliber, Thermo Scientific). Collision-
ally activated dissociation (CAD) of the ion at m/z 1571 gave a complex mass
spectrum that was analyzed using ProSightPC (Version 1.0; Thermo Scientific)
to match CAD product ions to the primary structure of ClC-ec1 with 1 or 2
OADS molecules placed at different positions.
Molecular Dynamics Simulations
The ClC-ec1 dimer (PDB entry 1OTS) (Dutzler, et al., 2003) was inserted in
a hydrated and equilibrated POPE/POPG(3:1) bilayer, set up with CHARMM-
GUI (Jo, et al., 2008), using g_membed (Wolf, et al., 2010). The system con-
tained 240 POPE lipids and 39 POPG lipids, 29509 TIP3P water molecules,
and KCl salt at 150 mM concentration. The CHARMM36 force field was
used together with the TIP3P water model (Klauda, et al., 2010). After energy
minimization and equilibration for 40 ns, eight molecules of OADS were in-
serted into the aqueous phase near the membrane. OADS was assumed to
be in a dianionic state and the parameters for OADS were derived using
CgenFF (Vanommeslaeghe, et al., 2010). See Supplemental Experimental
Procedures for further details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2012.09.017.
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